Penbrook Management’s Aquestive Therapeutics AQST Stock Holding History

Penbrook Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$191K	Sell	41,350 -1,950	-5%	-$8.66K	0.11%	95
2026 Q2	$180K	Buy	43,300 +17,735	+69%	+$74.6K	0.11%	98
2026 Q1	$106K	Sell	25,565 -16,595	-39%	-$67.4K	0.08%	90
2025 Q4	$272K	Sell	42,160 -1,425	-3%	-$8.88K	0.19%	77
2025 Q3	$244K	Hold	43,585	–	–	0.17%	85
2025 Q2	$144K	Buy	43,585 +21,000	+93%	+$60.2K	0.11%	91
2025 Q1	$65.5K	Buy	+22,585	New	+$68.4K	0.05%	105

Other funds holding AQST

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

SMAM

Sugar Maple Asset Management Sister Bay, Wisconsin $175M AUM 16.33% 1-Year Est. Return

ACA

Adirondack Capital Advisors Syracuse, New York $194M AUM 14.02% 1-Year Est. Return

CCM

Cox Capital Management Andover, Massachusetts $179M AUM 28.94% 1-Year Est. Return

Lineweaver Wealth Advisors Valley View, Ohio $863M AUM 14.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Penbrook Management's AQST Position: Q3 2026 in Review

Penbrook Management reduced its Aquestive Therapeutics (AQST) stake by 4.5% in Q3 2026, selling an estimated $8.66K and leaving 41,350 shares worth $191K. The position accounts for 0.11% of the portfolio, ranked #95.

Penbrook Management first reported a position in AQST in Q1 2025 and has held it in 7 quarters since. The position peaked at $272K in Q4 2025. 13 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

Penbrook Management held 41,350 shares of Aquestive Therapeutics worth $191K as of Q3 2026.
Penbrook Management sold 1,950 Aquestive Therapeutics shares in Q3 2026, an estimated $8.66K.
Aquestive Therapeutics made up 0.11% of Penbrook Management's portfolio in Q3 2026, its #95 holding.
Penbrook Management first reported a position in Aquestive Therapeutics in Q1 2025 and has held it in 7 quarters since.
Penbrook Management's Aquestive Therapeutics position peaked at $272K in Q4 2025.
13 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Penbrook Management's 13F filing for Q3 2026, filed 16 Oct 2026.